NCT06830759 Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
| NCT ID | NCT06830759 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AbbVie |
| Condition | Diffuse Large B-cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2025-03-28 |
| Primary Completion | 2031-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2025-03-28 with a primary completion date of 2031-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL. Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally. Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Eligibility Criteria
Inclusion Criteria: * Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL). * Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country. * The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study. Exclusion Criteria: * Any condition included in the contraindications section of the approved local epcoritamab label in the participating country. * Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.
Contact & Investigator
ABBVIE INC.
STUDY DIRECTOR
AbbVie
Frequently Asked Questions
Who can join the NCT06830759 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diffuse Large B-cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06830759 currently recruiting?
Yes, NCT06830759 is actively recruiting participants. Contact the research team at rebekah.taylor@abbvie.com for enrollment information.
Where is the NCT06830759 trial being conducted?
This trial is being conducted at Ciudad Autonoma de Buenos Aire, Argentina, Pilar, Argentina, Ciudad Autonoma de Buenos Aire, Argentina, Córdoba, Argentina and 11 additional locations.
Who is sponsoring the NCT06830759 clinical trial?
NCT06830759 is sponsored by AbbVie. The principal investigator is ABBVIE INC. at AbbVie. The trial plans to enroll 700 participants.